What is the share price of Parmax Pharma Ltd (PARMAX) today?
The share price of PARMAX as on 21st September 2026 is ₹136.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Parmax Pharma Ltd (PARMAX) share?
The past returns of Parmax Pharma Ltd (PARMAX) share are- Past 1 week: 1.00%
- Past 1 month: 5.00%
- Past 3 months: 96.60%
- Past 6 months: 432.81%
- Past 1 year: 314.34%
- Past 3 years: 336.62%
- Past 5 years: 234.72%
What are the peers or stocks similar to Parmax Pharma Ltd (PARMAX)?
The peers or stocks similar to Parmax Pharma Ltd (PARMAX) include:What is the market cap of Parmax Pharma Ltd (PARMAX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parmax Pharma Ltd (PARMAX) is ₹92.90 Cr as of 21st September 2026.What is the 52 week high and low of Parmax Pharma Ltd (PARMAX) share?
The 52-week high of Parmax Pharma Ltd (PARMAX) is ₹136.40 and the 52-week low is ₹22.60.What is the PE and PB ratio of Parmax Pharma Ltd (PARMAX) stock?
The P/E (price-to-earnings) ratio of Parmax Pharma Ltd (PARMAX) is -22.39. The P/B (price-to-book) ratio is -15.11.Which sector does Parmax Pharma Ltd (PARMAX) belong to?
Parmax Pharma Ltd (PARMAX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Parmax Pharma Ltd (PARMAX) shares?
You can directly buy Parmax Pharma Ltd (PARMAX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Parmax Pharma Ltd
PARMAX Share Price
BSE₹136.401.00% (+1.35)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PARMAX Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
PARMAX Performance & Key Metrics
PARMAX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -77.42 | -15.11 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.26 | 5.93 | 0.48% |
PARMAX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PARMAX Company Profile
Parmax Pharma Ltd engages in the production of active pharmaceutical ingredients (APIs) and contract manufacturing, adhering to cGMP standards for complex molecules.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
13.68%
13.68%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.94%
35.94%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
12.10%
12.10%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
10.12%
10.12%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
123.22%
123.22%
Buy Reco %
58.33
58.33
PARMAX Forecast
PARMAX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARMAX
PARMAX
Income
Balance Sheet
Cash Flow
Quarterly Normal View
PARMAX Income Statement
PARMAX Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.27 | 7.82 | 9.39 | 6.30 | 4.73 | 1.95 | 2.54 | 4.33 | 3.34 | 10.30 | ||||||||||
Operating & Other expenses | 5.06 | 7.30 | 9.08 | 6.18 | 6.46 | 2.19 | 4.12 | 4.52 | 4.86 | 7.39 | ||||||||||
EBITDA | -0.79 | 0.52 | 0.31 | 0.12 | -1.73 | -0.24 | -1.58 | -0.19 | -1.52 | 2.91 | ||||||||||
| Depreciation/Amortization | 0.41 | 0.40 | 0.40 | 0.41 | -0.18 | 0.24 | 0.26 | 0.27 | 0.25 | 0.48 | ||||||||||
| PBIT | -1.20 | 0.12 | -0.09 | -0.29 | -1.55 | -0.48 | -1.84 | -0.46 | -1.77 | 2.43 | ||||||||||
| Interest & Other Items | 0.16 | 0.11 | 0.13 | 0.11 | 0.24 | 0.28 | 0.24 | 0.28 | 0.50 | 0.23 | ||||||||||
| PBT | -1.36 | 0.01 | -0.22 | -0.40 | -1.79 | -0.76 | -2.08 | -0.74 | -2.27 | 2.20 | ||||||||||
| Taxes & Other Items | 0.09 | 0.00 | 0.00 | 0.00 | -0.30 | 0.00 | 0.00 | 0.00 | -1.69 | 0.00 | ||||||||||
| Net Income | -1.45 | 0.01 | -0.22 | -0.40 | -1.49 | -0.76 | -2.08 | -0.74 | -0.58 | 2.20 | ||||||||||
| EPS | -3.88 | 0.03 | -0.58 | -1.05 | -4.00 | -2.04 | -5.56 | -1.96 | -1.56 | 5.88 |
PARMAX Company Updates
PARMAX Stock Peers
PARMAX Past Performance & Peer Comparison
PARMAX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parmax Pharma Ltd | -22.39 | -15.11 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
PARMAX Stock Price Comparison
Compare PARMAX with any stock or ETFCompare PARMAX with any stock or ETF
PARMAX
PARMAX Holdings
PARMAX Shareholdings
PARMAX Promoter Holdings Trend
PARMAX Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 33.86%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PARMAX Institutional Holdings Trend
PARMAX Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 17.22%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARMAX Shareholding Pattern
PARMAX Shareholding Pattern
PARMAX Shareholding History
PARMAX Shareholding History
Foreign Institutions
smallcases containing PARMAX stock
smallcases containing PARMAX stock
Looks like this stock is not in any smallcase yet.
PARMAX Events
PARMAX Events
PARMAX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARMAX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PARMAX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARMAX has not given any dividends in last 5 years
PARMAX Dividends
PARMAX Dividends
Hmm, looks like data is unavailable here. Please come back after some timePARMAX Stock News & Opinions
PARMAX Stock News & Opinions
Articles & Videos
Corporate
Corporate
Shah family members acquire 11,52,450 shares, boosting stake in Parmax PharmaDhiren Chandulal Shah and Sunil Chinubhai Shah, along with Dhairya Dhiren Shah, Hiren Pravin Doshi, Sheetal Hiren Doshi, Nirmal Sunilbhai Shah, Vijaykumar Natvarlal Shiyani, and Kamlesh Natvarlal Shiyani, have acquired a total of 11,52,450 equity shares of Parmax Pharma Limited on August 13, 2026, pursuant to a share purchase agreement dated June 08, 2026. The acquisition, made through off-market transactions, increased the total shareholding of the acquirers and persons acting in concert from 27.20% to 58.01% of Parmax Pharma Limited's equity capital.
1 month agoCapital Market - Live
Corporate
Corporate
Parmax Pharma to announce Q2 2026 results Friday, August 14, followed by trading haltParmax Pharma Limited will hold a board meeting on Friday, August 14, 2026, to approve the unaudited standalone financial results for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. Trading in the company's securities will be closed for forty-eight hours after the announcement of the financial results, as per SEBI regulations.
1 month agoCapital Market - Live
Corporate
Corporate
Parmax Pharma to conduct EGMParmax Pharma announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 2 July 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Parmax Pharma to hold board meetingParmax Pharma will hold a meeting of the Board of Directors of the Company on 8 June 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Parmax Pharma reports standalone net loss of Rs 0.58 crore in the March 2026 quarterNet Loss of Parmax Pharma reported to Rs 0.58 crore in the quarter ended March 2026 as against net loss of Rs 1.49 crore during the previous quarter ended March 2025. Sales declined 31.47% to Rs 3.31 crore in the quarter ended March 2026 as against Rs 4.83 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 4.16 crore in the year ended March 2026 as against net loss of Rs 2.09 crore during the previous year ended March 2025. Sales declined 57.06% to Rs 12.11 crore in the year ended March 2026 as against Rs 28.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3.314.83 -31 12.1128.20 -57 OPM %-46.83-11.59 --30.140.92 - PBDT-2.02-0.90 -124 -4.84-0.29 -1569 PBT-2.27-0.72 -215 -5.85-1.32 -343 NP-0.58-1.49 61 -4.16-2.09 -99 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Parmax Pharma to discuss resultsParmax Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Parmax Pharma reports standalone net loss of Rs 0.73 crore in the December 2025 quarterNet Loss of Parmax Pharma reported to Rs 0.73 crore in the quarter ended December 2025 as against net loss of Rs 0.39 crore during the previous quarter ended December 2024. Sales declined 31.05% to Rs 4.33 crore in the quarter ended December 2025 as against Rs 6.28 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales4.336.28 -31 OPM %-4.391.91 - PBDT-0.460.02 PL PBT-0.73-0.39 -87 NP-0.73-0.39 -87 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Parmax Pharma to announce Quarterly ResultParmax Pharma will hold a meeting of the Board of Directors of the Company on 14 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Parmax Pharma reports standalone net loss of Rs 2.08 crore in the September 2025 quarterNet Loss of Parmax Pharma reported to Rs 2.08 crore in the quarter ended September 2025 as against net loss of Rs 0.22 crore during the previous quarter ended September 2024. Sales declined 72.74% to Rs 2.53 crore in the quarter ended September 2025 as against Rs 9.28 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2.539.28 -73 OPM %-62.852.05 - PBDT-1.820.18 PL PBT-2.08-0.22 -845 NP-2.08-0.22 -845 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Parmax Pharma announces board meeting dateParmax Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -14.29%, vs industry avg of 11.76%
Over the last 5 years, market share decreased from 0.01% to 0%